A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback